Case-Based Learning: Persistent Neutropenia After Resolution of Infection

Abstract

Persistent neutropenia following the resolution of an acute infection presents a diagnostic and management challenge for clinicians. This review synthesizes current evidence regarding epidemiology, mechanisms, risk factors, clinical presentation, diagnostic algorithm, and treatment options for prolonged neutropenia in the post-infectious setting. Special emphasis is placed on clinical decision-making, guideline-based evaluation, and emerging therapeutic approaches. The article aims to equip healthcare professionals with an in-depth understanding of persistent neutropenia to optimize patient outcomes and reduce complications.

Introduction

Neutropenia is a common hematological finding during acute infections; however, in most cases, neutrophil counts recover upon resolution of the inciting illness. Persistent neutropenia, defined as an absolute neutrophil count (ANC) below 1500/μL lasting longer than expected after infection clearance, raises concerns regarding underlying bone marrow dysfunction, immune dysregulation, or secondary pathology. Accurate identification of the etiology and appropriate management is crucial, as ongoing neutropenia increases the risk of opportunistic infections, impacts therapeutic decisions, and may unmask serious hematologic disorders. This review addresses the clinical and scientific aspects of persistent neutropenia post-infection, integrating recent research and expert recommendations for the practicing clinician.

Epidemiology / Disease Burden

The true incidence of persistent neutropenia after infection is not well established, as most cases of infection-associated neutropenia are transient. In pediatric populations, transient neutropenia is observed in up to 10% of children with viral infections, but persistence beyond four weeks is rare, occurring in less than 1%. In adults, persistent neutropenia is less common, but when present, is associated with increased morbidity due to secondary infections and hospitalizations. Recent cohort studies have highlighted that prolonged neutropenia post-infection is more frequently observed in immunocompromised individuals, the elderly, and those with chronic comorbidities. The burden is further compounded by the need for extensive diagnostic workups and the potential for delays in resuming immunosuppressive or cytotoxic therapies.

Pathophysiology

The pathogenesis of persistent neutropenia following infection is multifactorial. Mechanisms include direct viral suppression of myelopoiesis (e.g., parvovirus B19, hepatitis, HIV), immune-mediated destruction of neutrophils, and bone marrow exhaustion secondary to cytokine storm during severe infections. Cytokines such as interferon-γ and tumor necrosis factor-α may inhibit neutrophil production. Infections may also trigger the development of autoantibodies against neutrophil surface antigens, leading to peripheral destruction. In select cases, drug-induced marrow suppression (antibiotics, antivirals) or underlying hematologic malignancies become apparent only after infection resolution. The interplay between host genetics, immune response, and environmental factors determines the persistence and severity of neutropenia.

Risk Factors

Risk factors for persistent post-infectious neutropenia include advanced age, pre-existing immunodeficiency (congenital or acquired), recent or ongoing cytotoxic chemotherapy, underlying autoimmune disease, prior bone marrow suppression, and severe or prolonged infections. Certain pathogens, notably Epstein-Barr virus, cytomegalovirus, and hepatitis viruses, are more commonly associated with protracted neutropenia. Polypharmacy and exposure to myelosuppressive agents during infection management also contribute to risk. Genetic predispositions, such as benign ethnic neutropenia or polymorphisms in immune regulatory genes, may influence susceptibility and recovery dynamics.

Clinical Features

Persistent neutropenia may be asymptomatic initially, particularly if mild. However, moderate to severe neutropenia (ANC <1000/μL) raises the risk of recurrent or severe bacterial and fungal infections, oral ulcerations, mucositis, and delayed wound healing. Physical examination may be unremarkable or may reveal signs of ongoing infection, splenomegaly, lymphadenopathy, or mucocutaneous findings suggestive of autoimmune phenomena. The clinical course is often influenced by the underlying etiology and comorbid conditions. The temporal relationship to infection, drug exposures, and any family history of hematologic disorders should be carefully assessed.

Diagnosis

The diagnostic approach to persistent neutropenia post-infection is systematic and should begin with a thorough clinical history and physical examination. Laboratory assessment includes a complete blood count with differential, reticulocyte count, peripheral blood smear, and evaluation for hemolysis. Infections such as HIV, hepatitis, EBV, and CMV should be ruled out. Bone marrow aspiration and biopsy are indicated if there is associated cytopenia in other cell lines, blasts, or abnormal cells on smear, or if neutropenia persists beyond 6 weeks without a clear etiology. Autoimmune workup (ANA, anti-neutrophil antibodies), vitamin B12 and folate levels, and assessment for drug-induced causes are recommended. Flow cytometry and cytogenetic studies may be necessary in select cases. Early hematology consultation is advised for persistent, unexplained, or severe cases.

Treatment & Management

Management of persistent neutropenia is guided by the severity, underlying etiology, and risk of infection. In asymptomatic, mild cases with no evidence of ongoing infection or marrow failure, observation and serial monitoring may suffice. For moderate to severe neutropenia, prophylactic antibiotics or antifungals are considered in high-risk patients. Granulocyte colony-stimulating factor (G-CSF) may be administered in cases of severe neutropenia or if rapid neutrophil recovery is desired, particularly in the context of ongoing chemotherapy or planned immunosuppression. Treatable underlying causes such as vitamin deficiencies, drug-induced marrow suppression, or persistent infections should be addressed appropriately. Supportive care includes meticulous oral hygiene, prompt treatment of infections, and avoidance of myelosuppressive agents when possible.

Recent Advances / Emerging Therapies

Recent advances in the understanding of the immunogenetics of neutropenia have identified novel mutations and pathways amenable to targeted therapy. The use of next-generation sequencing panels has facilitated early diagnosis of congenital or clonal marrow disorders in patients with unexplained neutropenia. Monoclonal antibody therapies targeting immune-mediated neutropenia are under investigation, and novel agents modulating the bone marrow microenvironment may offer future therapeutic options. Ongoing clinical trials are exploring the efficacy and safety of biosimilar G-CSF formulations and the role of immunosuppressive therapy in autoimmune neutropenia resistant to conventional treatment.

Guideline Recommendations

Current guidelines from the American Society of Hematology and the Infectious Diseases Society of America recommend a risk-adapted approach to persistent neutropenia. Key recommendations include initial exclusion of reversible and infectious causes, early consideration of bone marrow examination in unexplained or severe cases, and judicious use of growth factors. Prophylactic antimicrobial therapy is reserved for patients at high risk for invasive infections. Multidisciplinary management involving hematology, infectious disease, and pharmacy teams is advised. Patient education regarding infection prevention and prompt reporting of symptoms is essential. Follow-up should be individualized based on severity and response to interventions.

Conclusion

Persistent neutropenia after resolution of infection necessitates a comprehensive, evidence-based approach to diagnosis and management. Clinicians must remain vigilant for underlying hematologic or immune-mediated disorders, employ a systematic workup, and tailor therapy according to patient risk. Advances in molecular diagnostics and novel therapeutics hold promise for improved outcomes. Adherence to guideline-based evaluation and multidisciplinary care is paramount to reducing complications and optimizing long-term health in affected individuals.